24. Juni 2025 – The clinical-stage biotech company headquartered in Basel, Switzerland, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body’s natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).

Walder Wyss advised the investors in this Series A financing round. The team was led by Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and further included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital), Michelle Bruni (Managing Associate, Tax), Simon Olstein (Senior Associate, Corporate/M&A), Oerjan Wickart (Associate, Corporate/M&A) and Dario Glauser (Associate, Employment).